figshare
Browse
ienz_a_2313055_sm8122.pdf (1.6 MB)

o-Vanillin binds covalently to MAL/TIRAP Lys-210 but independently inhibits TLR2

Download (1.6 MB)
journal contribution
posted on 2024-02-28, 19:40 authored by Md. Habibur Rahaman, Sara J. Thygesen, Michael J. Maxwell, Hyoyoung Kim, Prerna Mudai, Jeffrey D. Nanson, Xinying Jia, Parimala R. Vajjhala, Andrew Hedger, Irina Vetter, Thomas Haselhorst, Avril A. B. Robertson, Brian Dymock, Thomas Ve, Mehdi Mobli, Katryn J. Stacey, Bostjan Kobe

Toll-like receptor (TLR) innate immunity signalling protects against pathogens, but excessive or prolonged signalling contributes to a range of inflammatory conditions. Structural information on the TLR cytoplasmic TIR (Toll/interleukin-1 receptor) domains and the downstream adaptor proteins can help us develop inhibitors targeting this pathway. The small molecule o-vanillin has previously been reported as an inhibitor of TLR2 signalling. To study its mechanism of action, we tested its binding to the TIR domain of the TLR adaptor MAL/TIRAP (MALTIR). We show that o-vanillin binds to MALTIR and inhibits its higher-order assembly in vitro. Using NMR approaches, we show that o-vanillin forms a covalent bond with lysine 210 of MAL. We confirm in mouse and human cells that o-vanillin inhibits TLR2 but not TLR4 signalling, independently of MAL, suggesting it may covalently modify TLR2 signalling complexes directly. Reactive aldehyde-containing small molecules such as o-vanillin may target multiple proteins in the cell.

Funding

The work was supported by the National Health and Medical Research Council (grants 1196590 and 1108859 to T.V., 1160570 to B.K., K.J.S, M.M. and T.V., 2003688 to K.J.S., and 2025931 to B.K.) and the Australian Research Council Future Fellowship (FT200100572) to T.V. and Laureate Fellowship (FL180100109) to B.K.

History